These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17949891)

  • 1. Efficacy of delayed administration of post-chemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kinetics.
    Yankelevich M; Goodell MA; Kaplan J
    Exp Hematol; 2008 Jan; 36(1):9-16. PubMed ID: 17949891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloprotection following cytotoxic damage: the sooner the better.
    Hérodin F; Drouet M
    Exp Hematol; 2008 Jul; 36(7):769-70; author reply 771-2. PubMed ID: 18400359
    [No Abstract]   [Full Text] [Related]  

  • 3. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
    Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the in vivo administration of recombinant human granulocyte colony-stimulating factor following cytotoxic chemotherapy on granulocytic precursors in patients with malignant lymphoma.
    Ema H; Suda T; Sakamoto S; Tomonaga T; Tsunoda J; Muroi K; Komatsu N; Miwa A; Ohsaka A; Yoshida M
    Jpn J Cancer Res; 1989 Jun; 80(6):577-82. PubMed ID: 2474526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
    J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effect of granulocyte colony-stimulating factor or bacterial infection on bone-marrow cells of cyclophosphamide-treated or irradiated mice.
    Buisman AM; Van Zwet TL; Langermans JA; Geertsma MF; Leenen PJ; van Furth R
    Immunology; 1999 Aug; 97(4):601-10. PubMed ID: 10457213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed Granulocyte Colony-Stimulating Factor (G-CSF) Administration after Chemotherapy Reduces Total G-CSF Doses without Affecting Neutrophil Recovery in a Randomized Clinical Study in Children with Solid Tumors.
    Yankelevich M; Hoogstra DJ; Abrams J; Chu R; Bhambhani K; Taub JW
    Pediatr Hematol Oncol; 2020 Nov; 37(8):665-675. PubMed ID: 32643500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt-3 ligand.
    Liu F; Poursine-Laurent J; Link DC
    Blood; 1997 Oct; 90(7):2522-8. PubMed ID: 9326216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients.
    Lemoli RM; Fortuna A; Fogli M; Rosti G; Gherlinzoni F; Visani G; Catani L; Gozzetti A; Tura S
    Acta Haematol; 1996; 95(3-4):164-70. PubMed ID: 8677737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.
    Misaki M; Ueyama Y; Tsukamoto G; Matsumura T
    Br J Cancer; 1998 Mar; 77(6):884-9. PubMed ID: 9528829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization.
    Takamatsu Y; Simmons PJ; Moore RJ; Morris HA; To LB; Lévesque JP
    Blood; 1998 Nov; 92(9):3465-73. PubMed ID: 9787189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
    Yeung AW; Pang YK; Tsang YC; Wong SW
    Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice.
    Fazzi R; Testi R; Trasciatti S; Galimberti S; Rosini S; Piras F; L'Abbate G; Conte A; Petrini M
    Leuk Res; 2002 Jan; 26(1):19-27. PubMed ID: 11734300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer.
    Danova M; Rosti V; Mazzini G; De Renzis MR; Locatelli F; Cazzola M; Riccardi A; Ascari E
    Int J Cancer; 1995 Nov; 63(5):646-51. PubMed ID: 7591280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment.
    Lévesque JP; Hendy J; Takamatsu Y; Williams B; Winkler IG; Simmons PJ
    Exp Hematol; 2002 May; 30(5):440-9. PubMed ID: 12031650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.